A new drug, ataciguat, has shown promise in Treating Aortic Stenosis & slowing the progression of aortic stenosis (AS) and potentially reducing the need for TAVR or SAVR procedures.
Key Summary: A new drug, ataciguat, has shown promise in Treating Aortic Stenosis & slowing the progression of aortic stenosis (AS) and potentially reducing the need for TAVR or SAVR procedures.
• Research led by Mayo Clinic demonstrated that ataciguat reactivates oxidized soluble guanylate cyclase, limiting fibrocalcific aortic valve stenosis (FCAVS) progression.
• Phase I clinical trial confirmed the drug is well tolerated in patients with FCAVS.
• In a Phase II trial, six months of ataciguat treatment led to a ~70% reduction in aortic valve calcification progression compared to placebo.
• The drug also appeared to slow valvular and ventricular dysfunction, which reflects disease progression.
• Jordan Miller, PhD, emphasized that ataciguat could delay or prevent the need for valve replacement, significantly benefiting patients.
• Further large-scale clinical trials and long-term follow-up are needed to confirm ataciguat’s effectiveness in AS treatment.
• The study was a collaboration between Mayo Clinic, NIH, University of Minnesota, and Sanofi Pharmaceuticals, with Phase III trials already in progress.
This discovery represents a major step in non-surgical AS treatment, with potential implications for millions of patients.
Reference: Circulation 24 February 2025
